Successful Treatment of Stem Cell Graft Failure in Pediatric Patients Using a Submyeloablative Regimen of Campath-1H and Fludarabine

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 11, 2008, Pages 1298-1304

  Ahmed, Nabil ^a,b   Leung, Kathryn S ^a,b   Rosenblatt, Howard ^b   Bollard, Catherine M ^a,b,c   Gottschalk, Stephen ^a,b   Myers, Gary D ^a,b   Carrum, George ^a,c   Heslop, Helen E ^a,b,c   Brenner, Malcolm K ^a,b,c   Krance, Robert A ^a,b,c  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Campath 1H; Graft failure; HSCT; Pediatric; Submyeloablative

Indexed keywords

ALEMTUZUMAB; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS;

ADOLESCENT; ARTICLE; CHILD; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DONOR; DRUG EFFICACY; DRUG SAFETY; FAMILY; FEMALE; FOLLOW UP; GRAFT FAILURE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; LUNG TOXICITY; LYMPHOCYTE TRANSFUSION; MALE; METABOLIC DISORDER; MYCOSIS; NEUTROPENIA; NEUTROPHIL; NONMYELOABLATIVE CONDITIONING; RELAPSE; SEVERE COMBINED IMMUNODEFICIENCY; THROMBOCYTOPENIA; VIRUS INFECTION;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LIVING DONORS; LYMPHOCYTE TRANSFUSION; MALE; METABOLIC DISEASES; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SEVERE COMBINED IMMUNODEFICIENCY; SURVIVAL RATE; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 53749105338     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.09.003     Document Type: Article

References (33)

1. Davies S.M., Weisdorf D.J., Haake R.J., et al. Second infusion of bone marrow for treatment of graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 14 (1994) 73-77
2. Khouri I.F., and Keating M.J. High-dose chemotherapy for chronic lymphocytic leukemia: eligibility, timing, and benefit?. Ann Oncol 9 (1998) 131-132
3. Khouri I.F., Keating M., Korbling M., et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16 (1998) 2817-2824
4. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
5. Simpson D. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?. BioDrugs 17 (2003) 147-154
6. Aversa F., Tabilio A., Terenzi A., et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84 (1994) 3948-3955
7. Storb R., Blume K.G., O'Donnell M.R., et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 7 (2001) 39-44
8. Klangsinsirikul P., Carter G.I., Byrne J.L., et al. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 99 (2002) 2586-2591
9. Riechmann L., Clark M., Waldmann H., et al. Reshaping human antibodies for therapy. Nature 332 (1988) 323-327
10. Gilleece M.H., and Dexter T.M. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 82 (1993) 807-812
11. Wing M.G., Waldmann H., Isaacs J., et al. Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype. Ther Immunol 2 (1995) 183-190
12. Wing M.G., Moreau T., Greenwood J., et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 98 (1996) 2819-2826
13. Rowan W., Tite J., Topley P., et al. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 95 (1998) 427-436
14. Dyer M.J., Hale G., Hayhoe F.G., et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73 (1989) 1431-1439
15. Jabbour E., Rondon G., Anderlini P., et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant 40 (2007) 431-435
16. Strahm B., Locatelli F., Bader P., et al. Reduced-intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transplant 40 (2007) 329-333
17. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995) 825-828
18. Tsai T., Goodman S., Saez R., et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 20 (1997) 859-863
19. Ringden O., Labopin M., Frassoni F., et al. Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 24 (1999) 389-396
20. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 (1997) 4531-4536
21. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97 (2001) 631-637
22. Hows J.M. Mechanisms of graft failure after human marrow transplantation: a review. Immunol Lett 29 (1991) 77-80
23. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 10 (2001) 2942-2947
24. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 12 (2006) 560-565
25. Chewning J.H., Castro-Malaspina H., Jakubowski A., et al. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transplant 13 (2007) 1313-1323
26. Chakraverty R., Peggs K., Chopra R., et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99 (2002) 1071-1078
27. Hale G., and Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 91 (1998) 3079-3083
28. Kennedy-Nasser A.A., Leung K.S., Mahajan A., et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant 12 (2006) 1277-1284
29. Popat U., Carrum G., May R., et al. CD52 and CD45 monoclonal antibodies for reduced-intensity hemopoietic stem cell transplantation from HLA-matched and one antigen-mismatched unrelated donors. Bone Marrow Transplant 35 (2005) 1127-1132
30. Popat U., Heslop H.E., Durett A., et al. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant 37 (2006) 547-552
31. Kottaridis P.D., Milligan D.W., Chopra R., et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96 (2000) 2419-2425
32. Frassoni F., Strada P., Sessarego M., et al. Mixed chimerism after allogeneic marrow transplantation for leukaemia: correlation with dose of total body irradiation and graft-versus-host disease. Bone Marrow Transplant 5 (1990) 235-240
33. Mackinnon S., Papadopoulos E.B., Carabasi M.H., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86 (1995) 1261-1268